Biovail Appoints Vice President, International Marketing And Vice President And General Manager, Clinical Research Division

Business Wire, Feb 5, 1996

TORONTO--(BUSINESS WIRE)--February 5, 1996 --- Biovail Corporation International (AMEX, TSE:BVF) today announced the appointments of Marie-Claire Pilon as Vice President, International Marketing for Biovail Corporation effective February 5, 1996, and Paul R. Desjardins, Ph.D., as Vice President and General Manager of the Company's Clinical Research division, effective February 19, 1996.

Ms. Pilon, 41, has a strong clinical and marketing background gained through experience with many healthcare organizations in North America and Europe, including Benefit Research Group, France; Healthcare Forecasting Inc., United States; and Bristol-Myers Squibb, United States. Her experience from these organizations includes marketing, public relations and the coordination and management of drug related issues in conducting international clinical trials.

Dr. Desjardins, 52, is currently Head, Division of Laboratory Medicine and Pathology, and Head, Department of Clinical Chemistry, Health Sciences Centre, one of the largest hospital complexes in Canada, located in Winnipeg, Manitoba. He is also an Associate Professor in the Department of Biochemistry and Assistant Professor in the Department of Pathology at the University of Manitoba. Dr. Desjardins is a recipient of many awards and a well published author in clinical biochemistry. In addition, he chairs the publications division of the International Federation of -Clinical Chemistry and is involved with various clinical chemistry associations.

Eugene Melnyk, Chairman of the Board of Biovail commented, "We are pleased with these new additions to Biovail s senior management team. We are confident that Marie-Claire's international expertise in pharmaceutical marketing will have a significant impact on the international licensing of Tiazac as well as other Biovail products. Furthermore, Paul's expertise and stature in laboratory medicine will greatly enhance the Company's strategic and competitive position, specifically within Biovail's contract research division. The additions of Marie-Claire and Paul clearly demonstrate the Company s commitment to effectively serve the pharmaceutical industry through strategic growth and development.

Biovail Corporation International is an international full-service pharmaceutical company, engaged in the formulation, clinical evaluation, registration and manufacture of drug products utilizing advanced drug delivery technologies.

CONTACT: Biovail Corporation International

Eugene Melnyk, Bob Podruzny, 416/285-6000

or

Morgen-Walke Associates

Investor Relations: Donna Stein/

Courtney Levi/Cindy Hintelmann

Press: Michael McMullan, 212/850-5600